Legislator Brief · one page · drafted to be printed and carried into a meeting
Prior authorisation duration and automated denial
Automation may recommend a denial; a named clinician should have to own it.
Object type
Legislator Brief
Label
MODEL PAYER STANDARD
Status
OPEN FOR CRITIQUE
Jurisdiction
California / federal plans
Domain
Payer & prior authorization
Baseline verified
2026-08-30
Issue
An approved authorisation for chronic treatment expires on a schedule set by the payer, and adverse determinations can be produced by automated systems without a named clinician accountable for the decision.
Why now
Automated utilisation review is now in production at scale, and coverage transitions routinely interrupt stable treatment at the moment of greatest risk.
Current law
California law sets response timeframes and requires that denials on medical necessity be made by a licensed reviewer with appropriate expertise; federal interoperability rules set decision timelines for certain plans. Neither fixes authorisation duration nor bars automated final denial.
Policy gap
Duration, continuity across plan transition, and accountability for an automated determination are all unaddressed.
KPSGILL recommendation
Authorisation valid for the course of treatment or twelve months; ninety-day continuity on coverage transition; a named accountable clinician on every adverse determination; disclosure of automated involvement.
Who can act
Cost
Analysis, not projection. Payers bear review-cycle and system-change cost; the offsetting saving is fewer repeat reviews of approved chronic therapy. Net direction is genuinely uncertain and should be measured, not asserted.
Trade-offs
| Dimension | Direction | Basis |
|---|---|---|
| Access | ↑ increase | Continuity is the mechanism. |
| Physician burden | ↓ decrease | Fewer authorisation cycles per patient-year. |
| Government cost | ~ uncertain | Medi-Cal managed-care rates could move in either direction. |
| Innovation | ± mixed | Automation remains available for approval, not for final denial. |
| Administrative complexity | ↓ decrease | One duration rule replaces plan-by-plan schedules. |
| Litigation risk | ± mixed | A named accountable clinician creates a defendant and a deterrent. |
Who is affected
| Group | Expected impact | Why |
|---|---|---|
| Patients | strongly favorable | Stable therapy survives a plan change. |
| Physicians | strongly favorable | Removes the largest single source of repeat administrative work. |
| Insurers | strongly unfavorable | Constrains duration, timing and automation simultaneously. |
| Employers | mixed | Premium effect uncertain; absence and disruption effects favorable. |
| Government | favorable | Enforceable standard replaces case-by-case complaint handling. |
| Technology vendors | unfavorable | Automated final denial becomes unavailable as a product feature. |
Policy options
Option A — status quo
Duration set by payer; automated denial continues undisclosed.
Option B — limited reform
Extend timelines and require disclosure only. Leaves the interruption problem intact.
Option C — structural reform
Statutory duration floor, transition continuity, named clinician, automation disclosure, published overturn data.
Option D — KPSGILL preferred · preferred
C, sequenced: publish plan-level overturn rates first, because the published data is what makes the rest enforceable.
How we would know it worked
- Adverse determinations per thousand covered lives
- Overturn rate on internal appeal, by plan
- Therapy interruptions at coverage transition
- Median days from request to determination
- Share of determinations with a named accountable clinician
The five-physician practice
A five-physician practice has no authorisation staff. Duration is the variable that determines whether the work is survivable, which is why the floor matters more than the timeline.
Next decision point
DMHC rulemaking and the 2027 session; federal interoperability compliance dates for affected plans.
Model language and sources
Model statutory or regulatory language, the documentary baseline it rests on, the strongest arguments against the proposal and the KPSGILL responses to them are on the full page: Prior authorization: a duration floor and a named decision-maker. Related briefs are indexed at Legislator Briefs.